AAPL   366.37 (+0.62%)
MSFT   207.45 (+1.34%)
FB   234.07 (-1.47%)
NVDA   386.99 (+1.52%)
MU   50.22 (+1.05%)
GE   6.82 (+1.19%)
TSLA   1,209.24 (+8.00%)
T   30.30 (+1.30%)
GILD   76.69 (+0.82%)
DIS   112.89 (-0.12%)
AAPL   366.37 (+0.62%)
MSFT   207.45 (+1.34%)
FB   234.07 (-1.47%)
NVDA   386.99 (+1.52%)
MU   50.22 (+1.05%)
GE   6.82 (+1.19%)
TSLA   1,209.24 (+8.00%)
T   30.30 (+1.30%)
GILD   76.69 (+0.82%)
DIS   112.89 (-0.12%)
AAPL   366.37 (+0.62%)
MSFT   207.45 (+1.34%)
FB   234.07 (-1.47%)
NVDA   386.99 (+1.52%)
MU   50.22 (+1.05%)
GE   6.82 (+1.19%)
TSLA   1,209.24 (+8.00%)
T   30.30 (+1.30%)
GILD   76.69 (+0.82%)
DIS   112.89 (-0.12%)
AAPL   366.37 (+0.62%)
MSFT   207.45 (+1.34%)
FB   234.07 (-1.47%)
NVDA   386.99 (+1.52%)
MU   50.22 (+1.05%)
GE   6.82 (+1.19%)
TSLA   1,209.24 (+8.00%)
T   30.30 (+1.30%)
GILD   76.69 (+0.82%)
DIS   112.89 (-0.12%)
Log in

LON:IDHImmunodiagnostic Systems Share Price, Forecast & News

GBX 270
0.00 (0.00 %)
(As of 07/2/2020 03:36 PM ET)
Add
Compare
Today's Range
262
Now: GBX 270
270
50-Day Range
210
MA: GBX 238.20
305
52-Week Range
160
Now: GBX 270
420
Volume2,707 shs
Average Volume1,203 shs
Market Capitalization£79.52 million
P/E Ratio23.28
Dividend Yield0.79%
BetaN/A
Immunodiagnostic Systems Holdings PLC develops, manufactures, and sells in-vitro diagnostic tests to the clinical laboratory market in the United Kingdom, the United States, Germany, France, and internationally. It develops, manufactures, and markets immunoassays and automated immunoanalyser technologies to provide diagnostic outcomes for patients. It offers IDS-iSYS multi-discipline automated systems, which is based on chemiluminescence and absorbency technology is used for immunoassay testing. The company provides its products and services for diagnosis of bone metabolism, calcium metabolism, hypertension, chronic kidney disease mineral bone disorder, growth, fertility, autoimmunity, infectious disease, sarcoidosis, and allergy. Immunodiagnostic Systems Holdings PLC was founded in 1977 and is headquartered in Boldon, the United Kingdom.
Read More
Immunodiagnostic Systems logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 1.7Dividend Strength: 0.8Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.63 out of 5 stars


Industry, Sector and Symbol

Industry Medical Appliances & Equipment
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-191-5190660

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£39.35 million
Cash FlowGBX 105.41 per share
Book ValueGBX 193.80 per share

Profitability

Miscellaneous

Employees283
Market Cap£79.52 million
Next Earnings DateN/A
OptionableNot Optionable

Receive IDH News and Ratings via Email

Sign-up to receive the latest news and ratings for IDH and its competitors with MarketBeat's FREE daily newsletter.

Immunodiagnostic Systems (LON:IDH) Frequently Asked Questions

How has Immunodiagnostic Systems' stock been impacted by COVID-19 (Coronavirus)?

Immunodiagnostic Systems' stock was trading at GBX 240 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, IDH stock has increased by 12.5% and is now trading at GBX 270. View which stocks have been most impacted by Coronavirus.

How were Immunodiagnostic Systems' earnings last quarter?

Immunodiagnostic Systems Holdings PLC (LON:IDH) issued its earnings results on Wednesday, June, 20th. The company reported $5.70 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $2.60 by $3.10. View Immunodiagnostic Systems' earnings history.

How often does Immunodiagnostic Systems pay dividends? What is the dividend yield for Immunodiagnostic Systems?

Immunodiagnostic Systems declared a dividend on Wednesday, June 17th. Investors of record on Thursday, July 16th will be paid a dividend of GBX 1.90 per share on Friday, August 14th. This represents a dividend yield of 0.68%. The ex-dividend date of this dividend is Thursday, July 16th. This is an increase from Immunodiagnostic Systems's previous dividend of GBX 0.70. The official announcement can be accessed at this link. View Immunodiagnostic Systems' dividend history.

Has Immunodiagnostic Systems been receiving favorable news coverage?

Media coverage about IDH stock has trended very negative on Thursday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Immunodiagnostic Systems earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about Immunodiagnostic Systems.

Who are some of Immunodiagnostic Systems' key competitors?

What other stocks do shareholders of Immunodiagnostic Systems own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunodiagnostic Systems investors own include Dechra Pharmaceuticals (DPH), iShares Nasdaq Biotechnology ETF (IBB), Redrow (RDW), Netflix (NFLX), SYSCO (SYY), Tp Icap (TCAP), Telford Homes (TEF), WisdomTree U.S. Multifactor Fund (USMF), American Tower (AMT) and Advanced Medical Solutions Group (AMS).

Who are Immunodiagnostic Systems' key executives?

Immunodiagnostic Systems' management team includes the following people:
  • Mr. Jaap Stuut, CEO & Director (Age 49)
  • Mr. Paul J. Martin, Group Fin. Director, Company Sec. & Director
  • Nicola Mitton, Group HR Director
  • Mr. Ed Coombes, Head Of Bus. Devel. - Instrumentation (Age 48)
  • Dr. Rudolf Schemer, CEO of GeschTMaftsfuhrer at IDS GmbH Frankfurt & Country Mang. of Germany Region (Age 58)

What is Immunodiagnostic Systems' stock symbol?

Immunodiagnostic Systems trades on the London Stock Exchange (LON) under the ticker symbol "IDH."

How do I buy shares of Immunodiagnostic Systems?

Shares of IDH and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Immunodiagnostic Systems' stock price today?

One share of IDH stock can currently be purchased for approximately GBX 270.

How big of a company is Immunodiagnostic Systems?

Immunodiagnostic Systems has a market capitalization of £79.52 million and generates £39.35 million in revenue each year. Immunodiagnostic Systems employs 283 workers across the globe.

What is Immunodiagnostic Systems' official website?

The official website for Immunodiagnostic Systems is www.idsplc.com.

How can I contact Immunodiagnostic Systems?

Immunodiagnostic Systems' mailing address is 10 Didcot Way, BOLDON, NE35 9PD, United Kingdom. The company can be reached via phone at +44-191-5190660.

This page was last updated on 7/2/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.